Search by Drug Name, NDC or Jcode

    Internal Navigation

    HCPCS Details

    HCPC J2860
    Short Description Injection, siltuximab
    Long Description Injection, siltuximab, 10 mg
    Pricing indicator 51
    Coverage code C
    ASC payment group code YY
    BETOS2 code O1E
    Action code N
    Type of service 1
    Effective date 2016-01-01
    Date Added 2016-01-01

    HCPCS/NDC Cross-Walk

    NDC HCPC Description Drug Name Labeler Name HCPCS Dosage PKG Size PKG QTY Bill Units Bill Units PKG
    73090042001 J2860 Injection, siltuximab Sylvant EUSA PHARMA (UK) LIMITED 10 MG 1 1 10 10
    73090042101 J2860 Injection, siltuximab Sylvant EUSA PHARMA (UK) LIMITED 10 MG 1 1 40 40
    The ASP crosswalks are maintained by the Division of Data Analysis and Market Based Pricing to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to [email protected].

    HCPCS Billing Calculator

    Dosage given to patient (per dose)
    HCPCS Dosage 10 MG
    HCPCS/CPT Billing Units 0.1
    Total doses ordered
    Billing Units 0.1

    Drug Details

    • Siltuximab injection is used to treat multicentric Castleman's disease (MCD; abnormal overgrowth of lymph cells in more than one part of the body that may cause symptoms and may increase the risk of developing a serious infection or cancer) in people who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. Siltuximab is in a class of medications called monoclonal antibodies. It works by blocking the action of a natural substance that causes increased growth of lymph cells in people with MCD.